Search Results for "Immunizations"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Immunizations. Results 51 to 60 of 180 total matches.

In Brief: Pfizer/BioNTech COVID-19 Vaccine Authorized for Adolescents 12-15 Years Old

   
The Medical Letter on Drugs and Therapeutics • May 31, 2021  (Issue 1625)
In Brief: Pfizer/BioNTech COVID-19 Vaccine Authorized for Adolescents 12-15 Years Old ...
On May 10, 2021, the FDA expanded its Emergency Use Authorization (EUA) for the Pfizer/BioNTech mRNA-based COVID-19 vaccine to include adolescents 12-15 years old.1The vaccine has been authorized for use in persons ≥16 years old since December 2020.
Med Lett Drugs Ther. 2021 May 31;63(1625):81 |  Show IntroductionHide Introduction

In Brief: Pfizer/BioNTech COVID-19 Vaccine Authorized for Children 5-11 Years Old

   
The Medical Letter on Drugs and Therapeutics • Nov 29, 2021  (Issue 1638)
In Brief: Pfizer/BioNTech COVID-19 Vaccine Authorized for Children 5-11 Years Old ...
The FDA has issued an Emergency Use Authorization (EUA) for a lower-strength (10 mcg/0.2 mL) formulation of the mRNA-based COVID-19 vaccine manufactured by Pfizer/BioNTech (Comirnaty) for use in children 5-11 years old. The original formulation of (Comirnaty) (30 mcg/0.3 mL) is FDA-licensed for use in persons ≥16 years old and available under an EUA for use in adolescents 12-15 years old.
Med Lett Drugs Ther. 2021 Nov 29;63(1638):185 |  Show IntroductionHide Introduction

COVID-19 Updates

   
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022  (Issue 1642)
transplantation or have an equivalent level of immune compromise.1,2 2. Booster doses of the vaccine are now ...
On January 3, the FDA amended its Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine (Comirnaty) to incorporate the following changes. The anti-SARS-CoV-2 antibody combinations casirivimab plus imdevimab (REGEN-COV) and bamlanivimab plus etesevimab are not active against the Omicron variant of SARS-CoV-2.
Med Lett Drugs Ther. 2022 Jan 24;64(1642):16 |  Show IntroductionHide Introduction

COVID-19 Update: Booster Dose of the Pfizer Vaccine for Children 5-11 Years Old

   
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022  (Issue 1652)
COVID-19 Update: Booster Dose of the Pfizer Vaccine for Children 5-11 Years Old ...
The FDA has expanded its Emergency Use Authorization for the mRNA COVID-19 vaccine manufactured by Pfizer/BioNTech (Comirnaty) to include administration of a booster dose in children 5-11 years old who completed a primary series of the Pfizer vaccine ≥5 months previously.
Med Lett Drugs Ther. 2022 Jun 13;64(1652):94 |  Show IntroductionHide Introduction

Prevention and Treatment of Monkeypox

   
The Medical Letter on Drugs and Therapeutics • Sep 05, 2022  (Issue 1658)
vaccination) No Yes (at the vaccination site; can take ≥6 weeks to heal) Immune response 2 weeks after 2nd ...
An outbreak of monkeypox has recently spread around the globe and across the US. Updated information about the current outbreak is available from the CDC.
Med Lett Drugs Ther. 2022 Sep 5;64(1658):137-9 |  Show IntroductionHide Introduction

In Brief: Two Doses of Jynneos for Mpox (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 02, 2023  (Issue 5065)
Table 1) receive two doses of the Jynneos vaccine. The recommendation follows reports of a recent ...
The CDC is recommending that persons at high risk of mpox (see Table 1) receive two doses of the Jynneos vaccine. The recommendation follows reports of a recent cluster of mpox cases in the US and warnings about the risk of a renewed outbreak during the spring and summer as people gather for festivals and other events. The CDC does not recommend routine immunization against mpox for the general population.
Med Lett Drugs Ther. 2023 Jun 2;65(5065):1-2   doi:10.58347/tml.2023.5065a |  Show IntroductionHide Introduction

COVID-19 Updates

   
The Medical Letter on Drugs and Therapeutics • Apr 18, 2022  (Issue 1648)
COVID-19 UPDATES Second Booster Vaccine Dose for Older and Immunocompromised Persons The FDA ...
The FDA has expanded the Emergency Use Authorizations (EUAs) for the mRNA COVID-19 vaccines manufactured by Pfizer-BioNTech (Comirnaty) and Moderna (Spikevax) to allow for their use as a second booster dose ≥4 months after a first booster dose in adults ≥50 years old and in persons aged ≥12 years (Pfizer) or ≥18 years (Moderna) who have undergone solid organ transplantation or have a condition that compromises the immune system to a similar extent.
Med Lett Drugs Ther. 2022 Apr 18;64(1648):63-4 |  Show IntroductionHide Introduction

In Brief: Shingrix for Immunocompromised Adults

   
The Medical Letter on Drugs and Therapeutics • Aug 23, 2021  (Issue 1631)
recommendations from the Advisory Committee on Immunization Practices (ACIP) on use of the vaccine ...
The FDA has licensed the adjuvanted, recombinant varicella zoster virus (VZV) vaccine Shingrix (GSK) for prevention of herpes zoster (shingles) in adults of any age who are or will be at elevated risk because of disease- or therapy-induced immunodeficiency or immunosuppression. Shingrix has been licensed for herpes zoster prevention in adults ≥50 years old since 2017.1 It is the only VZV vaccine currently available in the US; Zostavax, a live-attenuated VZV vaccine, was withdrawn from the market in 2020.
Med Lett Drugs Ther. 2021 Aug 23;63(1631):129 |  Show IntroductionHide Introduction

Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19

   
The Medical Letter on Drugs and Therapeutics • Jan 10, 2022  (Issue 1641)
allergy that prevents their vaccination against COVID-19 or moderate or severe immune compromise (see ...
The FDA has issued an Emergency Use Authorization (EUA) for the investigational long-acting monoclonal antibodies tixagevimab and cilgavimab (Evusheld – AstraZeneca) to be administered concomitantly by IM injection for pre-exposure prophylaxis of COVID-19 in persons ≥12 years old who weigh ≥40 kg and have either a history of severe allergy that prevents their vaccination against COVID-19 or moderate or severe immune compromise (see Table 1). They are the first drugs to be authorized by the FDA for this indication. Two other pairs of antibodies, bamlanivimab plus etesevimab...
Med Lett Drugs Ther. 2022 Jan 10;64(1641):1-2 |  Show IntroductionHide Introduction

Figure 2: Pneumococcal Vaccine Recommendations for Adults ≥65 Years Old (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 14, 2024  (Issue 1713)
Figure 2: Pneumococcal Vaccine Recommendations for Adults ≥65 Years Old (online only) ...
View Figure 2: Pneumococcal Vaccine Recommendations for Adults ≥65 Years Old
Med Lett Drugs Ther. 2024 Oct 14;66(1713):e164   doi:10.58347/tml.2024.1713g |  Show IntroductionHide Introduction